Magic mushroom therapy for depression? new trial tests psilocybin and CBT in groups
NCT ID NCT07566104
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial will test whether giving psilocybin (the active ingredient in magic mushrooms) along with group cognitive behavioral therapy is acceptable and feasible for people with major depression. Thirty adults with current depressive symptoms will receive two doses of psilocybin (10 mg and 25 mg) plus 12 group therapy sessions. The study will measure satisfaction, retention, and changes in depression severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (a psychedelic drug) combined with cognitive behavioral therapy (a type of talk therapy)
What this could lead to
If this works, it could point toward a new treatment option for major depression that combines a psychedelic drug with group therapy.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply to everyone. Psilocybin can cause intense psychological effects and is not yet approved for depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA Semel Institute
Los Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••